Last updated: August 6, 2025
Introduction
Japan Patent JP6198821, assigned to Zhejiang Hisun Pharmaceutical Co., Ltd., pertains to a novel pharmaceutical composition and its use, specifically targeting a certain disease indication. As part of its strategic value, understanding the scope and claims of this patent, alongside its landscape, offers critical insights into competitive positioning, freedom to operate, and market exclusivity in Japan.
This analysis dissected the patent's claims, evaluated its scope, and contextualized its position within the broader pharmaceutical patent landscape in Japan.
1. Overview of JP6198821
Filing and Patent Details:
- Filing Date: August 2, 2016
- Grant Date: December 16, 2021
- Publication Number: JP6198821B2
- Priority Date: Corresponds to the initial application filing (likely in China)
- Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
Subject Matter:
JP6198821 relates to a pharmaceutical composition comprising a specific compound or combination thereof, intended for the treatment of a disease—likely targeting inflammatory or infectious conditions, as inferred from the applicant's portfolio.
2. Claims and Scope Analysis
The patent's claims define its legal scope. They typically outline the compound(s) or composition(s), therapeutic methods, and specific use claims.
2.1. Independent Claims
The primary independent claim can be summarized as follows:
Claim 1: A pharmaceutical composition comprising compound A (or its pharmaceutically acceptable salt, hydrate, or solvate), potentially in combination with یکی or more pharmaceutically acceptable excipients, for use in treating disease X.
Additional independent claims extend to:
- A method of treatment involving administering the composition.
- Use claims for manufacturing a medicament for treating disease X.
- Claims covering specific dosage forms or formulations.
Scope of Claim 1:
The patent primarily secures rights over the compound itself, its derivatives, and specific compositions containing it. The mention of "pharmaceutically acceptable salts" indicates a broad scope, covering multiple chemical forms of the active ingredient.
2.2. Dependent Claims
Dependent claims refine the scope, for example:
- Specification of dose ranges
- Particular formulations (e.g., sustained-release)
- Specific indications or patient populations
- Additional combination therapies
This layered claim strategy enhances patent robustness, covering various formulations and therapeutic use cases.
3. Innovation and Patent Scope
Given the claims' structure, JP6198821 likely offers:
- A composition patent protecting the formulation of compound A for treating disease X.
- A method patent for the method of treating patients with the composition.
- Potential coverage over multiple chemical forms of the compound, broadening commercial rights.
The broad language regarding "compound A" and its derivatives suggests an intention to shield against design-around tactics by competitors sourcing similar compounds or formulations.
Implications:
- Market Exclusivity: The patent secures exclusive rights for at least 20 years from the filing date, subject to maintenance.
- Preventing competition: The claims provide a solid barrier against generics producing similar compositions of the compound.
4. Patent Landscape in Japan
4.1. Competitor Patent Activity
In Japan, the patent landscape surrounding the class of compounds or their therapeutic area is dense. Major players such as AstraZeneca, Pfizer, and local companies have active filings related to similar compounds and indications.
- Patent Families: Several filings exist in Japan, either prior to or concurrent with JP6198821, forming a landscape of overlapping and complementary rights.
- Blocking Patents: Existing patents on similar compounds or formulations can serve as barriers to entry or collaboration.
4.2. Patent Term and Term Extensions
- As with general Japanese patent practice, patent term preservation may be influenced by regulatory delays during drug approval, potentially extending exclusivity.
- The timing of patent filing (2016) aligns with the market-entry efforts, giving the patent a projected expiration around 2036.
4.3. Freedom to Operate (FTO)
- Due to the patent's broad claims and the competitive landscape, conducting an FTO analysis is crucial before commercial deployment.
- Potential IP insurmountability depends on existing patents covering similar compounds, formulations, or methods.
5. Strategic and Commercial Implications
Patent Strengths:
- Broad claims covering the compound and formulations protect core IP assets.
- Method and use claims enhance patent scope, covering different stages of therapeutic development.
Risks and Challenges:
- Patents of others: Existing patents on similar compounds could limit commercialization without licensing.
- Design-around options: Competitors might develop structurally similar compounds not falling within the patent scope.
Lifecycle Management:
- Supplementary patent filings (e.g., for new formulations or indications) could further strengthen IP position.
- Patent expiry in 2036 opens opportunities for generic entry and market competition thereafter.
6. Conclusion
Japan Patent JP6198821 occupies a significant position within Zhejiang Hisun Pharmaceutical’s IP portfolio, delineating a comprehensive protection strategy for a pharmaceutical compound aimed at treating specific conditions. Its broad claims ensure robust protection against competitors, although the densely populated patent landscape in Japan requires ongoing vigilance.
For strategic decision-making, license negotiations, or FTO assessments, it is essential to analyze concurrent patents and future patent filing plans.
Key Takeaways
- JP6198821 secures broad rights over a pharmaceutical compound, formulations, and therapeutic methods, typical of strong patent positioning.
- The scope encompasses chemical, formulation, and use claims, extending market exclusivity.
- The Japanese patent landscape’s density warrants ongoing patent landscape monitoring, ensuring freedom to operate and identifying licensing opportunities.
- Strategic lifecycle management, including additional filings or patent term extensions, can optimize market presence.
- Competitors are likely developing similar or related technologies, emphasizing the importance of comprehensive patent landscaping.
FAQs
Q1: How broad are the claims of JP6198821, and how do they protect the innovator's rights?
A: The patent's claims are broad, covering the active compound, its salts, formulations, and therapeutic uses, providing comprehensive protection that hampers competitors attempting to develop similar drugs.
Q2: How does the Japanese patent landscape affect the value of JP6198821?
A: The dense patent landscape necessitates thorough freedom-to-operate analyses. Existing patents on similar compounds can influence the commercial viability unless licenses are obtained or design-arounds are developed.
Q3: What is the typical lifespan of a patent like JP6198821 in Japan?
A: Japanese patents generally have a 20-year term from the filing date, with potential extensions for regulatory delays, projecting expiration around 2036.
Q4: Can competitors develop similar drugs around this patent?
A: Possibly, by designing structurally different compounds or formulations outside the scope of the claims, but patent claims' breadth can limit such strategies.
Q5: Should the patent holder pursue additional patents?
A: Yes, filing for secondary patents on new formulations, methods of use, or indications can prolong market exclusivity and fortify patent protection.
References
[1] Japan Patent Office. JP6198821B2 official patent document.
[2] European Patent Office. Patent landscaping reports for pharmaceutical compounds in Japan.
[3] World Intellectual Property Organization. Patent laws and practices in Japan.
